Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer
Authors:
- Masahiro NatsuakiMNMasahiro Natsuaki
- Ken KozumaKKKen Kozuma
- Takeshi MorimotoTMTakeshi Morimoto
- Kazushige KadotaKKKazushige Kadota
- Toshiya MuramatsuTMToshiya Muramatsu
- Yoshihisa NakagawaYNYoshihisa Nakagawa
- Takashi AkasakaTATakashi Akasaka
- Keiichi IgarashiKIKeiichi Igarashi
- Kengo TanabeKTKengo Tanabe
- Yoshihiro MorinoYMYoshihiro Morino
- Tetsuya IshikawaTITetsuya Ishikawa
- Hideo NishikawaHNHideo Nishikawa
- 1 October 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 8 (10)
Abstract
Background—: There is a paucity of data reporting the clinical outcomes of biodegradable polymer biolimus-eluting stent (BP-BES) compared with durable polymer everolimus-eluting stent (DP-EES) beyond 1 year after stent implantation when the polymer is fully degraded. Methods and Results—: The NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial (NEXT) is a prospective, multicenter, randomized, open-label, noninferiority trial comparing BP-BES with DP-EES in patients scheduled for percutaneous coronary intervention using drug-eluting stent (DES) without any exclusion criteria among 98 participating centers in Japan. The trial was designed to evaluate noninferiority of BP-BES relative to DP-EES in terms of any target-lesion revascularization at 1 year and death or myocardial infarction at 3 years. Between May and October 2011, 3235 patients were randomly assigned to receive either BP-BES (1617 patients) or DP-EES (1618 patients). Complete 3-year follow-up was achieved in 97.6% of patients. At 3 years, the primary safety end point of death or myocardial infarction occurred in 159 patients (9.9%) in the BP-BES group and in 166 patients (10.3%) in the DP-EES group, demonstrating noninferiority of BP-BES relative to DP-EES ( P noninferiorityP superiority=0.7). Cumulative incidence of target-lesion revascularization was not significantly different between the 2 groups (7.4% versus 7.1%; P =0.8). By a landmark analysis at 1 year, the cumulative incidences of death or myocardial infarction and target-lesion revascularization were also not significantly different between the 2 groups (4.6% versus 5.2%; P =0.46 and 3.3% versus 2.7%; P =0.39, respectively). Conclusions—: Safety and efficacy outcomes of BP-BES were non inferior to those of DP-EES 3 years after stent implantation. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01303640.Keywords
This publication has 19 references indexed in Scilit:
- Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery DiseaseJACC: Cardiovascular Interventions, 2013
- Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting StentJACC, 2013
- Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trialThe Lancet, 2013
- Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis ModelKorean Circulation Journal, 2013
- Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trialsEuropean Heart Journal, 2012
- Very Late Stent Thrombosis and Late Target Lesion Revascularization After Sirolimus-Eluting Stent ImplantationCirculation, 2012
- Biodegradable Polymer Versus Permanent Polymer Drug-Eluting Stents and Everolimus- Versus Sirolimus-Eluting Stents in Patients With Coronary Artery DiseaseJACC, 2011
- Incidence and Risk Factors of Late Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation (3-Year Follow-Up of the j-Cypher Registry)The American Journal of Cardiology, 2010
- Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosisEuropean Heart Journal, 2008
- Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting StentCirculation, 2004